Publicacions en què col·labora amb Silvestre Vicent Cambra (9)

2023

  1. LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 6, pp. 1137-1154

  2. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1

2021

  1. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted

    Journal of Hepatology, Vol. 75, Núm. 2, pp. 363-376

  2. PDAC as an Immune Evasive Disease: Can 3D Model Systems Aid to Tackle This Clinical Problem?

    Frontiers in Cell and Developmental Biology, Vol. 9

2020

  1. The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas

    Journal of Clinical Investigation, Vol. 130, Núm. 4, pp. 1879-1895

2019

  1. Genetic mouse models as in vivo tools for cholangiocarcinoma research

    Cancers, Vol. 11, Núm. 12

  2. Inhibitor of differentiation-1 sustains mutant KRAS-driven progression, maintenance, and metastasis of lung adenocarcinoma via regulation of a FOSL1 network

    Cancer Research, Vol. 79, Núm. 3, pp. 625-638

2018

  1. Adjuvant therapy for colon cancer: Genes, genes. . . And the patient in the center

    Clinical Cancer Research, Vol. 24, Núm. 16, pp. 3787-3789

2017

  1. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer

    Nature Communications, Vol. 8